Genetic Code of E. Coli Is Hijacked by Biologists
By Nicholas Wade,
New York Times
| 07. 14. 2011
Synthetic biology, the quest to hijack living systems and convert them to human-directed goals, is on the march. Last year biologists synthesized the entire genome of a small bacterium and showed how it could successfully infect a second bacterium. Now, in what may be a more significant advance, biologists have shown they can radically change a genome, not just copy it.
A team led by Farren J. Isaacs and George M. Church of the Harvard Medical School has devised a method for making hundreds of changes in a genome simultaneously. This massively parallel intervention, as the changes are known, is one of the advances that would be needed in another project Dr. Church and others have contemplated, that of recreating the mammoth by starting with an elephant’s genome and changing it at the 400,000 sites at which elephant DNA differs from that of the mammoth.
In the present instance, Dr. Isaacs and Dr. Church have been working not with a mammoth but with the standard laboratory bacterium known as E. coli. To prove they can seize control of the microbe’s...
Related Articles
By Alondra Nelson, Science | 01.15.2026
One of the most interventionist approaches to technology governance in the United States in a generation has cloaked itself in the language of deregulation. In early December 2025, President Donald Trump took to Truth Social to announce a forthcoming “One...
By Daphne O. Martschenko and Julia E. H. Brown, Hastings Bioethics Forum | 01.14.2026
There is growing concern that falling fertility rates will lead to economic and demographic catastrophe. The social and political movement known as pronatalism looks to combat depopulation by encouraging people to have as many children as possible. But not just...
By Danny Finley, Bill of Health | 01.08.2026
The United States Food and Drug Administration (FDA) has a unique funding structure among federal scientific and health agencies. The industries it regulates fund nearly half of its budget. The agency charges companies a user fee for each application
...
By George Janes, BioNews | 01.12.2026
A heart attack patient has become the first person to be treated in a clinical trial of an experimental gene therapy, which aims to strengthen blood vessels after coronary bypass surgery.
Coronary artery bypass surgery is performed to treat...